1. Home
  2. NVCR vs VSAT Comparison

NVCR vs VSAT Comparison

Compare NVCR & VSAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • VSAT
  • Stock Information
  • Founded
  • NVCR 2000
  • VSAT 1986
  • Country
  • NVCR Switzerland
  • VSAT United States
  • Employees
  • NVCR N/A
  • VSAT N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • VSAT Radio And Television Broadcasting And Communications Equipment
  • Sector
  • NVCR Health Care
  • VSAT Technology
  • Exchange
  • NVCR Nasdaq
  • VSAT Nasdaq
  • Market Cap
  • NVCR 1.9B
  • VSAT 1.2B
  • IPO Year
  • NVCR 2015
  • VSAT 1996
  • Fundamental
  • Price
  • NVCR $17.71
  • VSAT $16.28
  • Analyst Decision
  • NVCR Buy
  • VSAT Buy
  • Analyst Count
  • NVCR 6
  • VSAT 7
  • Target Price
  • NVCR $32.83
  • VSAT $20.00
  • AVG Volume (30 Days)
  • NVCR 1.6M
  • VSAT 5.0M
  • Earning Date
  • NVCR 07-24-2025
  • VSAT 08-06-2025
  • Dividend Yield
  • NVCR N/A
  • VSAT N/A
  • EPS Growth
  • NVCR N/A
  • VSAT N/A
  • EPS
  • NVCR N/A
  • VSAT N/A
  • Revenue
  • NVCR $621,711,000.00
  • VSAT $4,519,571,000.00
  • Revenue This Year
  • NVCR $5.56
  • VSAT $4.46
  • Revenue Next Year
  • NVCR $9.19
  • VSAT $3.58
  • P/E Ratio
  • NVCR N/A
  • VSAT N/A
  • Revenue Growth
  • NVCR 18.27
  • VSAT 5.50
  • 52 Week Low
  • NVCR $14.17
  • VSAT $6.69
  • 52 Week High
  • NVCR $34.13
  • VSAT $26.70
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 51.32
  • VSAT 85.45
  • Support Level
  • NVCR $17.53
  • VSAT $14.31
  • Resistance Level
  • NVCR $18.70
  • VSAT $14.76
  • Average True Range (ATR)
  • NVCR 0.72
  • VSAT 0.90
  • MACD
  • NVCR 0.09
  • VSAT 0.26
  • Stochastic Oscillator
  • NVCR 60.56
  • VSAT 95.09

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About VSAT ViaSat Inc.

Viasat Inc provides bandwidth technologies and services in three segments: communication services and defense and advanced technologies. The communication services segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets, as well as for residential and enterprise fixed broadband customers: and the defense and advanced technologies segment develops and offers a diverse array of resilient, vertically integrated solutions to government and commercial customers, leveraging core technical competencies in encryption, cyber security, tactical gateways, modems and waveforms. A large majority of the firm's revenue is generated from communication services segment.

Share on Social Networks: